Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on NOVO NORDISK A/S
05/22 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
05/22 NOVO NORDISK A/S : Boost as drugs supplier gets Sh12m cold room
05/22 NOVO NORDISK A/S : Mission for Essential Drugs sets up Sh12m cold room for diabe..
05/17 NOVO NORDISK A/S : When diabetes and pro cycling meet
05/17 NOVO NORDISK A/S : Early response to Saxenda® resulted in weight maintenance and..
05/16 NOVO NORDISK A/S : DONG Energy - Historical partnership saves the climate from 2..
05/16 NOVO NORDISK A/S : Novelion CEO quits Novo Nordisk board due to NASH conflict
05/16 NOVO NORDISK A/S : Change in composition of the Board of Directors of Novo Nordi..
05/15 NOVO NORDISK A/S : - Share repurchase programme
05/11 NOVO NORDISK A/S : Launches Xultophy® 100/3.6 insulin degludec and liraglutide i..
05/11 NOVO NORDISK A/S : Clayton swaps YMCA land near Novo Nordisk
05/11 NOVO NORDISK A/S : Endocrine Society Lauds Novo Nordisk for Commitment to Afford..
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09 NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives a..
05/05 NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives a..
05/04 NOVO NORDISK A/S : Findings from Novo Nordisk in the Area of Type 2 Diabetes Des..
05/04 NOVO NORDISK A/S : SAB Biotherapeutics Strengthens Board of Directors with Appoi..
05/04 NOVO NORDISK A/S : Study Results from Novo Nordisk Update Understanding of N-Dem..
05/04 NOVO NORDISK A/S : New Findings from Novo Nordisk Describe Advances in Type 1 Di..
05/04 NOVO NORDISK A/S : Receives FDA Approval of Saxenda® liraglutide injection 3 mg ..
05/04 NOVO NORDISK A/S : increased reported operating profit by 10% in the first three..
05/04 NOVO NORDISK A/S : Launches Xultophy 100/3.6 (insulin degludec and liraglutide i..
05/04 NOVO NORDISK A/S : Benzalkonium Chloride Market 2017 - FeF Chemicals (Novo Nordi..
05/03 NOVO NORDISK A/S : beats 1Q profit forecasts
05/03DJNOVO NORDISK A/S : Narrows Guidance as Earnings Beat Forecasts
05/03 NOVO NORDISK A/S : increased reported operating profit by 10% in the first three..
05/02 NOVO NORDISK A/S : - Share repurchase programme
05/02 NOVO NORDISK A/S : to Attend Cell Line Development and Engineering Asia
04/28NOVO NORDISK A/S : quaterly earnings release
04/27 NOVO NORDISK A/S : New Data from Keio University Illuminate Findings in Anterior..
04/24 NOVO NORDISK A/S : - Reduction of the share capital
04/24 NOVO NORDISK A/S : - Share repurchase programme
04/22 NOVO NORDISK A/S : Leo Club, Novo Nordisk help intellectually challenged kids
04/21 XOMA CORPORATION (NASDAQ : XOMA) Files An 8-K Termination of a Material Definiti..
04/21 NOVO NORDISK A/S : - Reduction of the share capital
04/20 NOVOZYMES A/S : Researchers Submit Patent Application, "Subtilase Variants", for..
04/20 NOVO NORDISK A/S : Patent Issued for Automatic Injection Device with a Top Relea..
04/20 NOVO NORDISK A/S : Researchers from Novo Nordisk Discuss Findings in Proinsulin ..
04/20 FINDINGS FROM NOVO NORDISK YIELDS NE : Pharmacokinetic and...
04/18 NOVO NORDISK A/S (ADR)(NYSE : NVO) Recognizes The Hemophilia Community
04/14 NOVO NORDISK A/S : introduces new web-based portal that helps patients track the..
04/12 NOVO NORDISK A/S : The Ambassador speaks at the launch of Novo Nordisk programme..
04/12 Denmark's Novo A/S ups Synlab stake to 20 percent before possible IPO
04/12 NOVO NORDISK A/S : The Ambassador speaks at the launch of Novo Nordisk programme..
04/12 Just Three of World's Top 28 Pharmaceutical Corporations Agree to Match Pledg..
04/10 NOVO NORDISK A/S : - Share repurchase programme
04/08 NOVO NORDISK A/S : Pharmatech to Attend World Vaccine Congress
04/05 NOVO NORDISK A/S : MorphoSys Nominates New Candidate for Supervisory Board
04/03 NOVO NORDISK A/S : Status regarding Novo Nordisk's holding of its own shares (31..
04/03 NOVO NORDISK A/S : - Share repurchase programme
03/31 NOVO NORDISK A/S : FDA posts briefing materials prior to Advisory Committee meet..
03/30 NOVO NORDISK A/S : New Findings from Novo Nordisk Update Understanding of Athero..
03/29 NOVO NORDISK A/S : resubmits new drug application for fast-acting insulin aspart..
03/29 NOVO NORDISK A/S : resubmits new drug application for fast-acting insulin aspart..
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
03/28 UPDATE : Nordic, Avista To Sell 20% Stake In ConvaTec To Novo (ALLISS)
03/28 Nordic, Avista To Sell 20% Stake In ConvaTec, Further 15% In Placing (ALLISS)
03/27 NOVO NORDISK A/S : receives positive opinion from the European regulatory author..
03/27 NOVO NORDISK A/S : CHMP provides positive opinion for EU label update for Novo N..
03/27 NOVO NORDISK A/S : - Share repurchase programme
03/27 NOVO NORDISK A/S : Fiasp®, a new, ultra-fast acting mealtime insulin is availabl..
03/27 NOVO NORDISK A/S : New fast-acting mealtime insulin, Fiasp®, now approved and av..
03/27 NOVO NORDISK : Fiasp®, a new, ultra-fast acting mealtime insulin is available fo..
03/27 NOVO NORDISK A/S : Fiasp, New, Ultra-Fast Acting Mealtime Insulin Is Available f..
03/25 KELLER ROHRBACK L.L.P. : Files Class-Action Lawsuit Over the Inflated Price of I..
03/24 DONG Energy - Residues from Novo Nordisk and Novozymes to be converted into b..
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 NOVO NORDISK A/S : receives positive opinion from the European regulatory author..
03/24 NOVO NORDISK A/S : CHMP provides positive opinion for EU label update for Novo N..
03/24 NOVO NORDISK A/S : ex-dividend day for final dividend
03/23 NOVO NORDISK A/S : New Proinsulin Study Findings Reported from Novo Nordisk [Tot..
03/23 NOVO NORDISK A/S : Smithers Rapra's Extractables & Leachables USA 2017 program f..
03/23 NOVO NORDISK A/S : Resolutions from the Annual General Meeting of Novo Nordisk A..
03/20 NOVO NORDISK A/S : - Share repurchase programme
1  2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ( DKK)
Sales 2017 116 123 M
EBIT 2017 50 775 M
Net income 2017 38 089 M
Finance 2017 17 014 M
Yield 2017 2,80%
P/E ratio 2017 18,02
P/E ratio 2018 16,33
EV / Sales 2017 4,54x
EV / Sales 2018 4,34x
Capitalization 543 826 M
More Financials
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 282  DKK
Spread / Average Target 1,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S6.95%82 171
JOHNSON & JOHNSON10.23%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.11%191 279
MERCK & CO., INC.8.78%175 160
More Results